Zimmer Biomet Holdings, Inc. $ZBH Holdings Cut by Boston Trust Walden Corp

Boston Trust Walden Corp lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 499,389 shares of the medical equipment provider’s stock after selling 18,724 shares during the period. Boston Trust Walden Corp’s holdings in Zimmer Biomet were worth $44,361,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. BlackRock Inc. acquired a new stake in Zimmer Biomet during the 2nd quarter worth approximately $1,344,282,000. State Street Corp grew its stake in shares of Zimmer Biomet by 0.6% in the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after purchasing an additional 52,044 shares during the last quarter. Primecap Management Co. CA acquired a new position in shares of Zimmer Biomet in the second quarter valued at approximately $328,578,000. Dimensional Fund Advisors LP increased its holdings in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet during the second quarter worth approximately $187,480,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH opened at $109.46 on Thursday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $94.90 and its two-hundred day moving average is $91.89. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $112.55. The firm has a market capitalization of $20.88 billion, a PE ratio of 26.63, a P/E/G ratio of 2.33 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.90 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a $0.24 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.28% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Truist Financial increased their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Barclays raised shares of Zimmer Biomet to a “hold” rating in a research note on Wednesday, October 7th. Argus restated a “buy” rating and set a $125.00 price objective on shares of Zimmer Biomet in a research report on Thursday, October 22nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $105.68.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Adjusted Q3 earnings were $1.90 per share, ahead of analyst expectations, while revenue of $2.063 billion also beat estimates and increased 3.1% year over year. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Zimmer Biomet lifted its 2026 financial outlook. Strong hip and S.E.T. sales helped offset weaker knee performance, supporting the view that its product diversification is helping sustain growth. Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
• Positive Sentiment: The CEO said the company is not seeing a slowdown in orthopedic procedures, a reassuring demand signal for its core market. Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Negative Sentiment: Underlying challenges remain: knee sales were weak and margin pressure weighed on results. GAAP diluted EPS fell 13.8% to $1.00, while adjusted EPS of $1.90 was unchanged from a year earlier. Zimmer Biomet Q3 2026: How Diversification Offset a Weak Knee Quarter

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.